Whitepaper – The Value of Biomarkers from Discovery Through Commercialization

Why do some patients respond to therapy while others do not? The key lies in biomarkers—objective, measurable indicators that are revolutionizing disease diagnosis and driving every stage of drug development.

Accelerate Clinical Success with Proven Strategies

Biomarkers can triple pharmaceutical development success rates, offering:

• Faster proof-of-concept for novel therapeutic targets
• Accelerated prediction of drug efficacy, requiring fewer patients
• Superior patient stratification, for more meaningful clinical outcomes
• Use of surrogate endpoints to streamline regulatory decisions

Global Expertise, End-to-End Solutions

HBRI provides comprehensive support from discovery to clinical validation:

• Robust biomarker validation process, tailored to the latest platforms (ELISA, multiplex, NGS)
• Access to a network of over 700 laboratories and collection sites via Cerba HealthCare Group, ensuring seamless global logistics and premium sample integrity
• Direct scientist-to-scientist collaboration for customized solutions aligned to each development challenge

Bespoke Scientific Partnerships

From early discovery to commercialization, our team delivers:

• Validation of genetic, protein, and microbiome biomarkers
• Integration of companion diagnostics and prospective clinical sample collection
• Protocol optimization for more efficient studies and faster patient access

Fill the form to download the whitepaper